Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $58.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 2.05% year-over-year to $58.0 million, compared with a TTM value of $58.0 million through Dec 2025, up 2.05%, and an annual FY2025 reading of $58.0 million, up 2.05% over the prior year.
  • Shares Outstanding (Weighted Average) was $58.0 million for Q4 2025 at Agios Pharmaceuticals, roughly flat from $57.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $69.5 million in Q1 2021 and bottomed at $54.6 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $57.6 million, with a median of $56.8 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) decreased 21.55% in 2022, then rose 2.48% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $60.4 million in 2021, then decreased by 9.36% to $54.8 million in 2022, then increased by 1.57% to $55.7 million in 2023, then grew by 2.08% to $56.8 million in 2024, then rose by 2.05% to $58.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AGIO at $58.0 million in Q4 2025, $57.8 million in Q3 2025, and $57.7 million in Q2 2025.